PRTG - PORTAGE BIOTECH INC.
IEX Last Trade
5.02
0 0%
Share volume: 0
Last Updated: Thu 26 Dec 2024 02:30:39 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
3.82%
PREVIOUS CLOSE
CHG
CHG%
$5.02
0.00
0.00%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-12.92%
1 Month
9.96%
3 Months
-25.54%
6 Months
2,259.09%
1 Year
273.38%
2 Year
11.61%
Key data
Stock price
$5.02
DAY RANGE
$5.19 - $9.86
52 WEEK RANGE
$0.13 - $23.01
52 WEEK CHANGE
$207.10
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/29/2024
Company detail
CEO: Ian B. Walters
Region: US
Website: portagebiotech.com
Employees: 6
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: portagebiotech.com
Employees: 6
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Portage Biotech Inc. researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology.
Recent news